1,281
Views
33
CrossRef citations to date
0
Altmetric
REVIEW ARTICLE

MicroRNA in cancer: New hopes for antineoplastic chemotherapy

, &
Pages 202-216 | Received 05 Jan 2012, Accepted 16 Jan 2012, Published online: 21 Feb 2012

References

  • Bartel DP. MiRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
  • Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell. 2010;38:323–32.
  • Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell. 2008;132:9–14.
  • Miska EA, Alvarez-Saavedra E, Abbott AL, Lau NC, Hellman AB, McGonagle SM, Most Caenorhabditis elegans microRNAs are individually not essential for development or viability. PLoS Genet. 2007;3:e215.
  • Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26:3699–708.
  • Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, MicroRNA cluster 221–222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst. 2010;102:706–21.
  • Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27:5651–61.
  • Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res. 2009;15:5073–81.
  • Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;70:3638–46.
  • Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2011;18:74–82.
  • Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.
  • Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999–3004.
  • Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004;101:11755–60.
  • Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102:11755–60.
  • Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353:1793–801.
  • Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC, Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood. 2007;109:5079–86.
  • Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17:28–40.
  • Lia M, Carette A, Tang H, Shen Q, Mo T, Bhagat G, Functional dissection of the chromosome 13q14 tumor suppressor locus using transgenic mouse lines. Blood. 2011;Dec15 [Epub ahead of print].
  • Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113:6669–80.
  • Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271–7.
  • Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Saccà M, Memeo L, Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 2011;30:4231–42.
  • Cannell IG, Bushell M. Regulation of Myc by miR-34c. Cell Cycle. 2010;9:2726–30.
  • Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis. 2010;31:2066–73.
  • Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4:e6816.
  • Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 2008;17:236–45.
  • Antonini D, Russo MT, De Rosa L, Gorrese M, Del Vecchio L, Missero C. Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells. J Invest Dermatol. 2010;130:1249–57.
  • Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211–15.
  • Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res. 2008;6:735–42.
  • Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA. 2008;105:13421–6.
  • Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol. 2011;13:1353–60.
  • Chen L, Zheng J, Zhang Y, Yang L, Wang J, Ni J, Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther. 2011;19:1521–8.
  • Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137:1005–17.
  • Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010;24:2754–9.
  • Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66:11590–3.
  • Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle. 2009;8:843–52.
  • Bueno MJ, Pérez de Castro I, Gómez de Cedrón M, Santos J, Calin GA, Cigudosa JC, Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13:496–506.
  • Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009;137:1032–46.
  • Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010;18:367–81.
  • Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673–7.
  • O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435:839–43.
  • Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol. 2008;28:2167–74.
  • Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, Genetic dissection of the miR-17 ∼ 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009;23:2806–11.
  • Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C, Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell. 2008;132:860–74.
  • Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103:2257–61.
  • Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008;132:875–86.
  • Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat. 2009;117:131–40.
  • Huang GL, Zhang XH, Guo GL, Huang KT, Yang KY, Hu XQ. [Expression of microRNA-21 in invasive ductal carcinoma of the breast and its association with phosphatase and tensin homolog deleted from chromosome expression and clinicopathologic features]. Zhonghua Yi Xue Za Zhi. 2008;88:2833–7.
  • Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol. 2008;28:5369–80.
  • Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res. 2007;67:8994–9000.
  • Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–58.
  • Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009;49:1595–601.
  • Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008;54:1696–704.
  • Li J, Huang H, Sun L, Yang M, Pan C, Chen W, MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 2009;15:3998–4008.
  • Hummel R, Hussey DJ, Michael MZ, Haier J, Bruewer M, Senninger N, MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. Ann Surg Oncol. 2011;18:253–60.
  • Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest. 2008;88:1358–66.
  • Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27:2128–36.
  • Li Y, Zhu X, Gu J, Dong D, Yao J, Lin C, Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci. 2010;101:948–54.
  • Yao Q, Xu H, Zhang QQ, Zhou H, Qu LH. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem Biophys Res Commun. 2009;388:539–42.
  • Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, miR-21: an oncomir on strike in prostate cancer. Mol Cancer. 2010;9:12.
  • Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282:14328–36.
  • Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008;68:8164–72.
  • Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell. 2008;19:3272–82.
  • Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA. 2010;107:21098–103.
  • Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467:86–90.
  • Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 2010;18:282–93.
  • Ma X, Kumar M, Choudhury SN, Becker Buscaglia LE, Barker JR, Kanakamedala K, Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci USA. 2011;108:10144–9.
  • Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.
  • Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.
  • Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009;23:2140–51.
  • Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med. 2011;17:1101–8.
  • Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A, MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 2011;25:226–31.
  • Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2011;481:190–4.
  • Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98.
  • Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2010;29:1580–7.
  • Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011;19:1116–22.
  • Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437–47.
  • Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, Mets E, Taghon T, A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet. 2011;43:673–8.
  • Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011;147:1233–47.
  • Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet. 2011;43:371–8.
  • Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008;27:3845–55.
  • Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283:29897–903.
  • Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011;30:1082–97.
  • Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O, Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 2010;127:1785–94.
  • Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P, The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69:3356–63.
  • Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010;10:367.
  • Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425–36.
  • Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 2011;300:197–204.
  • Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther. 2011;131:18–32.